According to the Australian guide, what concise treatment recommendations for bronchiectasis are, and what red‑flag signs and referral criteria should be used?

Bronchiectasis Management According to Australian Guidelines

Treat bronchiectasis with intensive airway clearance by a respiratory physiotherapist, 14-day antibiotic courses for exacerbations based on sputum cultures, and long-term antibiotics (macrolides or inhaled colistin) for patients with ≥3 exacerbations per year. 1

Core Treatment Approach

Airway Clearance (Foundation of Management)

• Individualized airway clearance techniques (ACTs) taught by respiratory physiotherapists 1, 2
• Regular exercise encouraged 1
• Despite being cornerstone therapy, only 52% of Australian patients actually perform ACTs despite 71% having chronic productive cough 3

Acute Exacerbations

• 14-day antibiotic courses (not the typical 5-7 days used for other respiratory infections) 1
• Base antibiotic selection on:
  • Lower airway culture results (sputum samples essential)
  • Local antibiotic susceptibility patterns
  • Clinical severity
  • Patient tolerance 1
• Hospitalize if: severe exacerbation or not responding to outpatient therapy for IV antibiotics and intensive ACTs 1

Long-Term Antibiotic Therapy

Indication: ≥3 exacerbations per year 4

For Pseudomonas aeruginosa colonization:

1. First-line: Inhaled colistin 1 MU twice daily via I-neb 4
2. Second-line: Inhaled gentamicin 4
3. Alternative: Azithromycin 250mg 3x/week or erythromycin (if inhaled antibiotics not tolerated) 4

For other pathogens or no pathogen: Long-term macrolides 4, 5

Safety checks before starting:

• Macrolides: Exclude active NTM infection (at least one negative respiratory NTM culture) 4
• Inhaled aminoglycosides: Avoid if creatinine clearance <30 mL/min; use caution with significant hearing loss or balance issues 4

What NOT to Use Routinely

• Inhaled corticosteroids (unless concurrent asthma/COPD) - yet 48% of Australian patients receive them inappropriately 3
• Long-acting bronchodilators (unless concurrent asthma/COPD) 5
• Recombinant human DNase in non-CF bronchiectasis 4

Additional Management

• Vaccinations: Influenza and pneumococcal per national schedules 1, 5
• Pulmonary rehabilitation: For impaired exercise capacity (indicated in 67% but only 22% attend in Australia) 5, 3
• Smoking cessation: Essential 5
• Optimize nutrition 1
• Avoid air pollutants 1

---

Red Flags Requiring Urgent Action

Clinical Deterioration Indicators

• Increasing exacerbation frequency and/or severity 6
• Worsening symptoms despite treatment 6
• Rapid decline in lung function 6
• Massive hemoptysis 7
• Not responding to oral antibiotics within expected timeframe 1, 2

Microbiological Red Flags

• New Pseudomonas aeruginosa detection - requires eradication therapy 1
• Non-tuberculous mycobacteria (NTM) infection - especially if deteriorating despite appropriate antibiotics 6
• Allergic bronchopulmonary aspergillosis (ABPA) 4, 6

Radiological Red Flags

• Progressive radiological changes on repeat CT 6
• Features suggestive of NTM infection 6

---

When to Refer to Respiratory Specialist

Mandatory Referrals

1. At diagnosis - for baseline assessment and investigation of underlying cause 1
2. Deteriorating patients not already under specialist care 6
3. Before starting long-term antibiotics - prophylactic antibiotics should only be started by respiratory specialists 4
4. Before starting DMARDs or biologics (in patients with rheumatoid arthritis and bronchiectasis) 4
5. Consideration for lung resection - highly selected patients with localized disease uncontrolled by optimal medical therapy 6
6. Early referral for lung transplantation - FEV₁ <30% predicted and/or PaCO₂ >50 mmHg despite optimal management 6

Ongoing Specialist Care Required For

• 6-monthly monitoring for complications and comorbidities 1, 2
• Review of long-term antibiotics every 6 months (efficacy, toxicity, continuing need) 4
• Sputum culture monitoring - only 59% of Australian patients have bacterial cultures and 29% have mycobacterial cultures available 3

High-Risk Features Warranting Specialist Input

• ≥5 exacerbations per year (may need regular IV antibiotics every 2-3 months) 4
• Chronic Pseudomonas aeruginosa infection 4
• Immunodeficiency or connective tissue disease 4, 5
• Significant comorbidities (COPD, rheumatoid arthritis) - associated with worse mortality 4

---

Common Pitfalls to Avoid

1. Under-reporting chronic wet cough - key symptom often missed 2
2. Not obtaining sputum cultures before starting antibiotics 8, 3
3. Using short antibiotic courses (<14 days) for exacerbations 1
4. Routine use of inhaled corticosteroids without asthma/COPD indication 4, 5
5. Not checking for NTM before starting macrolides 4
6. Poor access to pulmonary rehabilitation despite clear indication 3
7. Not assessing treatment adherence when patients deteriorate 6